Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
What therapy would you use for a patient with metastatic TFE3 rearranged RCC who progressed on initial pembrolizumab/lenvatinib?
Related Questions
In what situations do you escalate the dose of Axitinib over 5 mg bid when administered with Pembrolizumab for clear cell RCC?
When considering cytoreductive nephrectomy in metastatic kidney cancer, in which situations would you consider nephron-sparing approaches such as partial nephrectomy or SBRT?
How are you utilizing subcutaneous Nivolumab in genitourinary cancers?
What are your top takeaways from ASCO GU 2025?
How do you manage recurrent asymptomatic transaminitis from VEGF TKI in a patient renal cell carcinoma who needs drug to control disease?
What would you offer for a very young patient with metastatic renal medullary carcinoma who has progressed on cisplatin-based chemotherapy?
In a patient with de novo metastatic RCC s/p Ipi/Nivo with partial response and residual viable RCC on cytoreductive nephrectomy, would you add cabozantinib or other TKI prior to disease progression?
Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?
In light of recent updates on neoadjuvant enfortumab vedotin plus pembrolizumab for muscle-invasive bladder cancer showing benefit, how should a trimodality bladder-preservation strategy be contextualized?
How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?
